These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23331217)

  • 1. Editors' note on special issue on medical product safety.
    Tsong Y; Chen J
    J Biopharm Stat; 2013; 23(1):1-2. PubMed ID: 23331217
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA issues guidelines for biosimilar drugs.
    Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

  • 4. What's best for the patient?
    Burkle WS
    Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
    [No Abstract]   [Full Text] [Related]  

  • 5. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US drug shortages are set to reach record high in 2011, report says.
    Tanne JH
    BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug safety: the obligation of information recognized in Washington].
    Chneiweiss H
    Med Sci (Paris); 2009 Mar; 25(3):317. PubMed ID: 19361399
    [No Abstract]   [Full Text] [Related]  

  • 8. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

  • 9. LyphoMed sparks worries.
    Wagner M
    Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
    [No Abstract]   [Full Text] [Related]  

  • 10. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinguishing product and practice regulation in personalized medicine.
    Evans BJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):288-93. PubMed ID: 17259953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint.
    Ley HL; Desmond FH
    Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100
    [No Abstract]   [Full Text] [Related]  

  • 15. Should herbal medicines be regulated as drugs?
    McGuffin M
    Clin Pharmacol Ther; 2008 Mar; 83(3):393-5. PubMed ID: 18285785
    [No Abstract]   [Full Text] [Related]  

  • 16. Parenteral nutrition product shortages: impact on safety.
    Holcombe B
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):44S-47S. PubMed ID: 22282871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA and the fight against terrorism.
    Meadows M
    FDA Consum; 2004; 38(1):20-7. PubMed ID: 15032200
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug Product Problem Reporting Program.
    FDA Drug Bull; 1979 Aug; 9(3):18. PubMed ID: 467875
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
    Wigle WW
    Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
    [No Abstract]   [Full Text] [Related]  

  • 20. Compounding vs standardized commercial parenteral nutrition product: pros and cons.
    Gervasio J
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):40S-41S. PubMed ID: 22301324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.